Roche targets mid-single digit sales growth in 2025 with robust pipeline momentum
Roche projects mid-single digit group sales growth in 2025, with core EPS growth in the high-single digit range. The company expects a CHF1.2 billion impact from the loss of exclusivity but aims to ...
PLTY: Palantir-Linked ETF Follows YieldMax Script But Won't Prevent Big Loss
Explore Palantir's success in data utilization, challenges, and the evolving investing landscape. Click for more on YieldMax ...
F. Hoffmann-La Roche Ltd: Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.